188 related articles for article (PubMed ID: 27814993)
1. Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study.
Wang L; Heckman MG; Aasly JO; Annesi G; Bozi M; Chung SJ; Clarke C; Crosiers D; Eckstein G; Garraux G; Hadjigeorgiou GM; Hattori N; Jeon B; Kim YJ; Kubo M; Lesage S; Lin JJ; Lynch T; Lichtner P; Mellick GD; Mok V; Morrison KE; Quattrone A; Satake W; Silburn PA; Stefanis L; Stockton JD; Tan EK; Toda T; Brice A; Van Broeckhoven C; Uitti RJ; Wirdefeldt K; Wszolek Z; Xiromerisiou G; Maraganore DM; Gasser T; Krüger R; Farrer MJ; Ross OA; Sharma M;
Neurobiol Aging; 2017 Jan; 49():217.e1-217.e4. PubMed ID: 27814993
[TBL] [Abstract][Full Text] [Related]
2. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease.
Brown EE; Blauwendraat C; Trinh J; Rizig M; Nalls MA; Leveille E; Ruskey JA; Jonvik H; Tan MMX; Bandres-Ciga S; Hassin-Baer S; Brockmann K; Infante J; Tolosa E; Ezquerra M; Ben Romdhan S; Benmahdjoub M; Arezki M; Mhiri C; Hardy J; Singleton AB; Alcalay RN; Gasser T; Grosset DG; Williams NM; Pittman A; Gan-Or Z; Fernandez-Santiago R; Brice A; Lesage S; Farrer M; Wood N; Morris HR;
Neurobiol Aging; 2021 Jan; 97():148.e17-148.e24. PubMed ID: 32873436
[TBL] [Abstract][Full Text] [Related]
3. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
4. Establishing the role of rare coding variants in known Parkinson's disease risk loci.
Jansen IE; Gibbs JR; Nalls MA; Price TR; Lubbe S; van Rooij J; Uitterlinden AG; Kraaij R; Williams NM; Brice A; Hardy J; Wood NW; Morris HR; Gasser T; Singleton AB; Heutink P; Sharma M;
Neurobiol Aging; 2017 Nov; 59():220.e11-220.e18. PubMed ID: 28867149
[TBL] [Abstract][Full Text] [Related]
5. Fine mapping and resequencing of the PARK16 locus in Parkinson's disease.
Pihlstrøm L; Rengmark A; Bjørnarå KA; Dizdar N; Fardell C; Forsgren L; Holmberg B; Larsen JP; Linder J; Nissbrandt H; Tysnes OB; Dietrichs E; Toft M
J Hum Genet; 2015 Jul; 60(7):357-62. PubMed ID: 25855069
[TBL] [Abstract][Full Text] [Related]
6. MAPT IVS1+124 C>G modifies risk of LRRK2 G2385R for Parkinson's disease in Chinese individuals.
Dan X; Wang C; Ma J; Feng X; Wang T; Zheng Z; Chan P
Neurobiol Aging; 2014 Jul; 35(7):1780.e7-1780.e10. PubMed ID: 24559644
[TBL] [Abstract][Full Text] [Related]
7. LRRK2-associated Parkinson's disease patients have better stereopsis than idiopathic Parkinson disease.
Sun L; Chan P
Clin Neurol Neurosurg; 2018 Jun; 169():174-177. PubMed ID: 29705653
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
von Linstow CU; Gan-Or Z; Brundin P
Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
[TBL] [Abstract][Full Text] [Related]
9. Association of ZNF184, IL1R2, LRRK2, ITPKB, and PARK16 with sporadic Parkinson's disease in Eastern China.
Gao T; Zheng R; Ruan Y; Fang Y; Jin C; Cao J; Song Z; Tian J; Pu J; Zhang B
Neurosci Lett; 2020 Sep; 735():135261. PubMed ID: 32682840
[TBL] [Abstract][Full Text] [Related]
10. Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus.
Tan EK; Kwok HH; Tan LC; Zhao WT; Prakash KM; Au WL; Pavanni R; Ng YY; Satake W; Zhao Y; Toda T; Liu JJ
Neurology; 2010 Aug; 75(6):508-12. PubMed ID: 20697102
[TBL] [Abstract][Full Text] [Related]
11. Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?
Biernacka JM; Armasu SM; Cunningham JM; Ahlskog JE; Chung SJ; Maraganore DM
Parkinsonism Relat Disord; 2011 Dec; 17(10):730-6. PubMed ID: 21816655
[TBL] [Abstract][Full Text] [Related]
12. Functional variants in the
Hui KY; Fernandez-Hernandez H; Hu J; Schaffner A; Pankratz N; Hsu NY; Chuang LS; Carmi S; Villaverde N; Li X; Rivas M; Levine AP; Bao X; Labrias PR; Haritunians T; Ruane D; Gettler K; Chen E; Li D; Schiff ER; Pontikos N; Barzilai N; Brant SR; Bressman S; Cheifetz AS; Clark LN; Daly MJ; Desnick RJ; Duerr RH; Katz S; Lencz T; Myers RH; Ostrer H; Ozelius L; Payami H; Peter Y; Rioux JD; Segal AW; Scott WK; Silverberg MS; Vance JM; Ubarretxena-Belandia I; Foroud T; Atzmon G; Pe'er I; Ioannou Y; McGovern DPB; Yue Z; Schadt EE; Cho JH; Peter I
Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321258
[TBL] [Abstract][Full Text] [Related]
13. Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG; Labbé C; Kolicheski AL; Soto-Beasley AI; Walton RL; Valentino RR; Brennan ER; Johnson PW; Baheti S; Sarangi V; Ren Y; Uitti RJ; Wszolek ZK; Ross OA
Parkinsonism Relat Disord; 2021 Feb; 83():22-30. PubMed ID: 33454605
[TBL] [Abstract][Full Text] [Related]
14. Clinical Features of LRRK2 Carriers with Parkinson's Disease.
Kestenbaum M; Alcalay RN
Adv Neurobiol; 2017; 14():31-48. PubMed ID: 28353277
[TBL] [Abstract][Full Text] [Related]
15. Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson's disease.
Rizig M; Ojo OO; Athanasiou-Fragkouli A; Agabi OP; Oshinaike OO; Houlden H; Okubadejo NU
Neurobiol Aging; 2021 Mar; 99():101.e15-101.e19. PubMed ID: 33158606
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.
Sosero YL; Yu E; Krohn L; Rudakou U; Mufti K; Ruskey JA; Asayesh F; Laurent SB; Spiegelman D; Fahn S; Waters C; Sardi SP; Bandres-Ciga S; Alcalay RN; Gan-Or Z; Senkevich K
Neurobiol Aging; 2021 Jul; 103():142.e1-142.e5. PubMed ID: 33781610
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.
Satake W; Nakabayashi Y; Mizuta I; Hirota Y; Ito C; Kubo M; Kawaguchi T; Tsunoda T; Watanabe M; Takeda A; Tomiyama H; Nakashima K; Hasegawa K; Obata F; Yoshikawa T; Kawakami H; Sakoda S; Yamamoto M; Hattori N; Murata M; Nakamura Y; Toda T
Nat Genet; 2009 Dec; 41(12):1303-7. PubMed ID: 19915576
[TBL] [Abstract][Full Text] [Related]
18. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk.
MacLeod DA; Rhinn H; Kuwahara T; Zolin A; Di Paolo G; McCabe BD; Marder KS; Honig LS; Clark LN; Small SA; Abeliovich A
Neuron; 2013 Feb; 77(3):425-39. PubMed ID: 23395371
[TBL] [Abstract][Full Text] [Related]
19. Models of LRRK2-Associated Parkinson's Disease.
Xiong Y; Dawson TM; Dawson VL
Adv Neurobiol; 2017; 14():163-191. PubMed ID: 28353284
[TBL] [Abstract][Full Text] [Related]
20. CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.
Loeffler DA; Smith LM; Coffey MP; Aasly JO; LeWitt PA
J Neural Transm (Vienna); 2016 Mar; 123(3):179-87. PubMed ID: 26526034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
